Drug Trial Radar · NCT05959239
TB006 Expanded Access (EA) Compassionate Use
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- TrueBinding, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 55 years
Summary
As written by the sponsor on the registry.
This is an open-label, expanded access, compassionate use treatment protocol of TB006 treatment in participants who meet clinical diagnostic criteria for Alzheimer's disease (AD). Participants will receive TB006 at a dose of 4,000 milligrams (mg) intravenous (IV) over 1 hour every 28 days ± 5 days.
Conditions
- Alzheimer Disease
Interventions
TB006Drug
TB006 will be provided as single-use injectable glass vials.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.